Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
-
BUSINESS Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
-
REGULATORY Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
-
BUSINESS Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
-
REGULATORY MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
-
BUSINESS DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
-
BUSINESS Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
-
BUSINESS Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
-
ORGANIZATION EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
-
BUSINESS Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
-
REGULATORY MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
-
ORGANIZATION Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
-
BUSINESS Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
-
BUSINESS HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
-
BUSINESS Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
-
REGULATORY Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
-
BUSINESS China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
-
ORGANIZATION 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
-
BUSINESS RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto
July 16, 2012
-
ORGANIZATION Wholesaler FTC to Make Serious Efforts for Improving “Services of Convenience”
July 13, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…